Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS108 in advanced solid tumors
NCT04601285Phase 1Terminated
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Oct 2020
- Primary completion
- Jun 2023
- Countries
- 1
01
Overview
Phase 1, open-label trial of DAC-002 in solid tumor (advanced stage), sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoints: First Cycle Dose Limiting Toxicities at 21 days and Adverse Events at 1 year. Started Oct 2020; status: terminated.
02
Drugs
DAC-002
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04601285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04601285.